Waterstone Pharmaceuticals (HuBei) Co., Ltd.

Primary objective: To evaluate the safety and tolerability of WS012 after single and multiple oral administration in healthy Chinese adult subjects. Secondary objective: To evaluate the pharmacodynamics of total bile acid (TBA) and fecal TBA in WS012 after single and multiple oral administration in healthy Chinese adult subjects. Exploratory objective: To explore the effects of multiple oral administration of WS012 on blood lipids (TG, TC, HDL-C, LDL-C) in healthy subjects.

To preliminarily evaluate the efficacy and safety of WS016 dry suspension in the treatment of hyperkalemia.

Primary objective: To evaluate the tolerability and safety of single-dose ascending and multiple-dose ascending oral administration of WS016 in healthy subjects. Secondary objective: To study the pharmacodynamic (PD) characteristics of single-dose ascending and multiple-dose ascending oral administration of WS016 in healthy subjects, evaluate the changes in serum potassium, urine and fecal potassium excretion compared with baseline, and provide a basis for the dosing regimen of Phase II clinical trials. Exploratory objective: To explore the effects of oral administration of WS016 on blood electrolytes (sodium, magnesium, calcium) in healthy subjects.